IP Library Granted Patent US 7,858,117
Granted Patent B2
US 7,858,117 · App. 11/745,003 · Granted Dec 28, 2010

Amphoteric liposomes and their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,117
App. No.
11/745,003
Granted
Dec 28, 2010
Kind
B2
Abstract

Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.

Claims (24)

1. An amphoteric liposome comprising an active ingredient, having an isoelectric point of between 4 and 7, wherein the liposome comprises at least one amphipathic cationic lipid, at least one amphipathic anionic lipid, and at least one neutral lipid, and wherein the liposome is stable at pH 4.2 and Ph 7.5.

2. The amphoteric liposome of claim 1 , wherein the liposome has an isoelectric point of between 5 and 7.

3. The amphoteric liposome of claim 1 , wherein the neutral lipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, cholesterol, tetraether lipid, ceramide, sphingolipid, and diacyl glycerol.

4. The amphoteric liposome of claim 1 wherein the anionic lipid is a weak anion and the cationic lipid is a strong cation, and the anion is present in excess over the cation.

5. The amphoteric liposome of claim 4 , wherein the weak anion is selected from the group consisting of cholesterol hemisuccinate (CHEMS), diacyl glycerol hemisuccinate, fatty acids and phosphatidyl serine.

6. The amphoteric liposome of claim 4 , wherein the strong cation is selected from the group consisting of DOTAP, DC-Chol, DORIE, DDAB, TC-Chol, DOTMA, DOGS, (C18) 2 Gly + N, N-dioctadecylamido-glycin, CTAB, CpyC and DOEPC.

7. The amphoteric liposome of claim 4 , wherein the anionic lipid is CHEMS, diacylglycerol hemisuccinate, or a fatty acid, the cationic lipid is DOTAP or DC-Chol and the neutral lipid is present at 10-60 mol. %.

8. The amphoteric liposome of claim 4 , wherein the neutral lipid is present at about 10-20 mol .%.

9. The amphoteric liposome of claim 4 , wherein the neutral lipid is cholesterol.

10. The amphoteric liposome of claim 4 , wherein the neutral lipid is phosphatidylcholine.

11. The amphoteric liposome of claim 1 , wherein the anionic lipid is a weak anion and the cationic lipid is a weak cation.

12. The amphoteric liposome of claim 11 , wherein the weak anion is selected from the group consisting of cholesteryl hemisuccinate (CHEMS), diacyl glycerol hemisuccinate, fatty acids and phosphatidyl serine.

13. The amphoteric liposome of claim 11 , wherein the weak cation is selected from the group consisting of HisChol and MoChol.

14. The amphoteric liposome of claim 11 , wherein the anionic lipid is CHEMS or diacylglycerol hemisuccinate, the cationic lipid is HisChol or MoChol and the neutral lipid is present at 10-60 mol. %.

15. The amphoteric liposome of claim 11 , wherein the neutral lipid is present at 10-20 mol. %.

16. The amphoteric liposome of claim 11 , wherein the neutral lipid is present at 20-50 mol. %.

17. The amphoteric liposome of claim 11 , wherein the neutral lipid is cholesterol.

18. The amphoteric liposome of claim 11 , wherein the neutral lipid is phosphatidylcholine.

19. The amphoteric liposome of claim 11 , wherein the neutral lipid comprises phosphatidylcholine and phosphatidylethanolamine.

20. The amphoteric liposome of claim 1 , wherein the active ingredient is a protein, a peptide, a DNA, and RNA, antisense nucleotide and/or a decoy nucleotide.

21. The amphoteric liposome of claim 1 , wherein at least 80 percent of the active ingredient is in the interior of the liposome.

22. The amphoteric liposome of claim 1 , wherein the liposome has an average size of between 50 and 1000 nm.

23. The amphoteric liposome of claim 22 , wherein the liposome has an average size of between 70 and 250 nm.

24. The amphoteric liposome of claim 22 , wherein the liposome has an average size of between 60 and 130 nm.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2020
From: MONSANTO COMPANY
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 053171/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2020
From: ADHERA THERAPEUTICS, INC.
To: NOVOSOM VERWALTUNGS GMBH
Reel/Frame 052955/0256 →
CHANGE OF NAME Recorded Jun 16, 2020
From: MARINA BIOTECH, INC.
To: ADHERA THERAPEUTICS, INC.
Reel/Frame 052957/0901 →
CHANGE OF NAME Recorded Jun 16, 2020
From: BIONTECH PROTEIN THERAPEUTICS GMBH
To: BIONTECH DELIVERY TECHNOLOGIES GMBH
Reel/Frame 052957/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2020
From: NOVOSOM VERWALTUNGS GMBH
To: BIONTECH PROTEIN THERAPEUTICS GMBH
Reel/Frame 052958/0867 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →